Viva Biotech Holdings (HK:1873)
:1873
Want to see HK:1873 full AI Analyst Report?
Top Page
Viva Biotech Holdings
(1873)
Select Model
Select Model
Rating:53Neutral
Price Target:
HK$1.50
▼(-14.77% Downside)
Action:ReiteratedDate:04/24/26
The score is primarily supported by improved profitability and a stronger leverage profile, but it is held back by deteriorating 2025 cash-flow momentum and ongoing revenue decline. Technically, the stock remains in a clear downtrend (below key moving averages with negative MACD), which further pressures the overall rating, while valuation appears only moderate based on the provided P/E.
Positive Factors
Return to profitability
The company returned to solid net profits in 2024–2025 after loss years, demonstrating restored earnings capacity. Sustained profitability improves internal funding for R&D and partnering activities, reduces refinancing pressure and supports longer-term operational stability.
Negative Factors
Multi-year revenue decline
A persistent top-line contraction, including an 8.3% fall in 2025, undermines scale economics and constrains long-term margin expansion. Continued revenue decline limits the ability to grow operating profits and fund R&D or partnerships organically over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Return to profitability
The company returned to solid net profits in 2024–2025 after loss years, demonstrating restored earnings capacity. Sustained profitability improves internal funding for R&D and partnering activities, reduces refinancing pressure and supports longer-term operational stability.
Read all positive factors
Viva Biotech Holdings (1873) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$3.53B
Dividend YieldN/A
Average Volume (3M)10.31M
Price to Earnings (P/E)15.9
Beta (1Y)2.20
Revenue Growth-12.90%
EPS Growth33.65%
CountryHK
Employees2,063
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.05
Shares Outstanding2,129,882,300
10 Day Avg. Volume10,852,121
30 Day Avg. Volume10,305,290
Financial Highlights & Ratios
PEG Ratio0.61
Price to Book (P/B)0.85
Price to Sales (P/S)2.03
P/FCF Ratio38.77
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$4.00Price Target Upside127.27% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.12
Revenue Forecast (FY)HK$2.17B
Viva Biotech Holdings Business Overview & Revenue Model
Company Description
Viva Biotech Holdings, an investment holding company, provides structure-based drug discovery services to biotechnology and pharmaceutical customers worldwide. The company provides discovery biology services, include protein expression and purific...
How the Company Makes Money
null...
Viva Biotech Holdings Financial Statement Overview
Summary
Income Statement
62
Positive
Balance Sheet
70
Positive
Cash Flow
48
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.68B | 1.99B | 2.16B | 2.38B | 2.10B |
| Gross Profit | 638.59M | 687.40M | 738.43M | 815.68M | 650.98M |
| EBITDA | 393.84M | 428.00M | 391.01M | 436.35M | 369.94M |
| Net Income | 214.07M | 167.29M | -116.11M | -528.48M | 287.55M |
Balance Sheet | |||||
| Total Assets | 7.20B | 7.05B | 7.45B | 7.92B | 8.04B |
| Cash, Cash Equivalents and Short-Term Investments | 1.13B | 941.58M | 1.04B | 678.57M | 800.95M |
| Total Debt | 1.33B | 1.28B | 1.90B | 2.82B | 2.65B |
| Total Liabilities | 3.19B | 3.23B | 3.76B | 4.32B | 4.13B |
| Stockholders Equity | 4.00B | 3.80B | 3.69B | 3.60B | 3.91B |
Cash Flow | |||||
| Free Cash Flow | 88.02M | 182.32M | 195.57M | 136.72M | -487.35M |
| Operating Cash Flow | 206.04M | 373.99M | 383.40M | 386.05M | 77.83M |
| Investing Cash Flow | -93.76M | 185.90M | 439.17M | -372.80M | -868.84M |
| Financing Cash Flow | 36.61M | -657.76M | -429.50M | -143.20M | -653.16M |
Viva Biotech Holdings Technical Analysis
Negative
1.76
Price Trends
2.15
Negative
2.08
Negative
2.14
Negative
Market Momentum
-0.06
Negative
44.24
Neutral
42.31
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1873, the sentiment is Negative. The current price of 1.76 is below the 20-day moving average (MA) of 1.94, below the 50-day MA of 2.15, and below the 200-day MA of 2.14, indicating a bearish trend. The MACD of -0.06 indicates Negative momentum. The RSI at 44.24 is Neutral, neither overbought nor oversold. The STOCH value of 42.31 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:1873.
Viva Biotech Holdings Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | HK$41.41B | 34.57 | 25.67% | ― | 16.65% | 0.87% | |
53 Neutral | HK$3.53B | 15.94 | 5.53% | ― | -12.90% | 33.65% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | HK$9.60B | 30.77 | 24.17% | ― | 154.21% | ― | |
50 Neutral | HK$42.28B | -18.01 | -14.44% | ― | 34.19% | 47.97% |
* Healthcare Sector Average
HK:1873
Viva Biotech Holdings
1.67
0.20
13.61%
HK:1877
Shanghai Junshi Biosciences Co., Ltd. Class H
26.68
10.34
63.28%
HK:2096
Simcere Pharmaceutical Group Limited
11.92
3.30
38.28%
HK:2157
Lepu Biopharma Co. Ltd. Class H
5.32
0.28
5.56%
HK:2696
Shanghai Henlius Biotech, Inc. Class H
76.20
37.25
95.64%
HK:6955
Shandong Boan Biotechnology Company., Limited. Class H
6.81
-3.51
-34.01%
Viva Biotech Holdings Corporate Events
Viva Biotech Sets 2026 AGM to Approve Accounts, Board Changes and Share Issuance Mandate
Apr 22, 2026
Viva Biotech Holdings has convened its annual general meeting for June 26, 2026, in Shanghai to seek shareholder approval on a range of standard corporate matters. Shareholders will be asked to receive the audited financial statements for the year...
Viva Biotech Profits Rise in 2025 Despite Revenue Decline
Mar 30, 2026
Viva Biotech Holdings reported 2025 revenue of RMB 1.73 billion, down 12.9% from a year earlier, but improved profitability, with gross profit slipping only 4.6% to RMB 655.6 million and gross margin rising to 37.9% from 34.6%. Net profit increase...
Viva Biotech Sets March 30 Board Meeting to Approve 2025 Results
Mar 18, 2026
Viva Biotech Holdings has scheduled a board meeting for March 30, 2026 to review and approve the group’s audited annual results for the financial year ended December 31, 2025. The board will also decide whether to recommend a final dividend ...
Viva Biotech Non-Executive Director Stephen Wang Resigns With Immediate Effect
Feb 16, 2026
Viva Biotech Holdings announced the immediate resignation of non-executive director Stephen Hui Wang, who is stepping down to devote more time to his personal and business commitments. The board emphasized that Wang has no disagreements with the c...
Viva Biotech Sets Out Board and Committee Structure
Feb 16, 2026
Viva Biotech Holdings has disclosed the current composition of its board of directors, detailing the roles of its executive, non-executive, and independent non-executive members. The announcement also outlines the membership and chairmanship of th...
Viva Biotech Wins Green Light to Expand Peptide Production at Zhejiang Subsidiary
Jan 29, 2026
Viva Biotech Holdings announced that its wholly owned subsidiary, Zhejiang Langhua Pharmaceutical, has received official approval from the Taizhou Ecological Environment Bureau for its environmental impact report covering a plan to remodel three e...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.